What will Amgen say during their next earnings call? — On Feb 2, 2027
Markets
Every market on this event, moneyline first. Select one to compare it across platforms in the side panel.
| Outcome | Best | Volume | Gemini | Kalshi | Limitless | Novig | Polymarket | Polymarket US |
|---|---|---|---|---|---|---|---|---|
GLP-1 / GLP No liquidity | — | — | — | No liquidity94.0% | — | — | — | — |
Dazodalibep No liquidity | — | — | — | No liquidity94.0% | — | — | — | — |
Eosinophilic No liquidity | — | — | — | No liquidity94.0% | — | — | — | — |
VESALIUS-CV No liquidity | — | — | — | No liquidity78.0% | — | — | — | — |
Oral (3+ times) No liquidity | — | — | — | No liquidity75.0% | — | — | — | — |
Tavneos No liquidity | — | — | — | No liquidity63.0% | — | — | — | — |
Acquisition No liquidity | — | — | — | No liquidity51.0% | — | — | — | — |
Prolia (2+ times) No liquidity | — | — | — | No liquidity45.0% | — | — | — | — |
Medicare No liquidity | — | — | — | No liquidity60.0% | — | — | — | — |
Imfinzi / Durvalumab No liquidity | — | — | — | No liquidity56.0% | — | — | — | — |
ESMO No liquidity | — | $1 | — | No liquidity36.0% | — | — | — | — |
Litigation No liquidity | — | — | — | No liquidity30.0% | — | — | — | — |
Buyback / Buy Back No liquidity | — | — | — | No liquidity21.0% | — | — | — | — |
Artificial Intelligence (3+ times) No liquidity | — | — | — | No liquidity34.0% | — | — | — | — |
Patent (2+ times) No liquidity | — | — | — | No liquidity34.0% | — | — | — | — |
Description from Kalshi. A cross-platform summary is generated once this event is matched across platforms.
How this is resolved Video of Amgen earnings call. If a consensus by Kalshi employees cannot be reached using video, transcripts of Amgen earnings call will be used according to the news publications listed in the contract. Payout criteria The exact phrase/word, or a plural or possessive form of the phrase/word. Doesn't count for payout Grammatical/tense inflections. Kalshi is not affiliated, associated, authorized, endorsed by, or in any way officially connected with the Amgen corporation. All trademarks, logos, and brand names are the property of their respective owners.
Discussion (0)
Log in to join the discussion.
No comments yet — start the discussion.